<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">Colorectal cancers</z:e> associated with <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> are characterized by deficient DNA mismatch repair (MMR) function </plain></SENT>
<SENT sid="1" pm="."><plain>Our aim was to evaluate the prevalence of microsatellite instability (MSI) and loss of MMR protein expression in <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>-associated <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Sixty-two colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath>--37 <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath>, 23 <z:mpath ids='MPATH_140'>hyperplastic polyps</z:mpath>, and 2 sessile serrated <z:mpath ids='MPATH_491'>polyps</z:mpath> (SSP)--from 34 subjects with germline MMR gene mutations were tested for MSI using a single pentaplex PCR for five <z:chebi fb="0" ids="29075">mononucleotide</z:chebi> repeat microsatellite markers, and also for expression of MLH1, MSH2, MSH6, and PMS2 proteins by immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>High-level MSI (MSI-H) was seen in 15 of 37 (41%) <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath>, one of 23 (4%) <z:mpath ids='MPATH_140'>hyperplastic polyps</z:mpath>, and one of two (50%) SSPs </plain></SENT>
<SENT sid="4" pm="."><plain>Loss of MMR protein expression was seen in 18 of 36 (50%) <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath>, zero of 21 <z:mpath ids='MPATH_140'>hyperplastic polyps</z:mpath>, and zero of two SSPs </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_490'>Adenomatous polyps</z:mpath> 8 mm or larger in size were significantly more likely to show MSI-H [OR, 9.98; 95% confidence interval (CI), 1.52-65.65; P = 0.02] and deficient MMR protein expression (OR, 3.17; 95% CI, 1.20-8.37; P = 0.02) compared with those less than 8 mm in size </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> (six of six) <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> 10 mm or larger in size showed both MSI-H and loss of MMR protein expression by immunohistochemistry </plain></SENT>
<SENT sid="7" pm="."><plain>Our finding that the prevalence of MMR deficiency increases with the size of <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> suggests that loss of MMR function is a late event in <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>-associated colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Although testing large <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> may be of value in the diagnostic evaluation of patients with suspected <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>, the absence of an MMR-deficient phenotype in an <z:mpath ids='MPATH_270'>adenoma</z:mpath> cannot be considered as a strong evidence against <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>, as it is with colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
</text></document>